First Trust Nasdaq Pharmaceuticals ETF Rating $36.02 0.00 (0.00%) As of 06/12/2026 03:49 PM Eastern Add Compare Share Share Ratings Stock AnalysisChartDividendHoldingsOptions ChainOwnershipRatingsShort InterestTrendsBuy This Stock First Trust Nasdaq Pharmaceuticals ETF Aggregate Rating and Price Target (2026)How MarketBeat Aggregates ETF Rating and Price TargetMarketBeat calculates the aggregate rating and price target for an ETF by considering the weight of each stock in its portfolio. These ratings and price targets are based on the most recent ratings given by Wall Street analysts over the past year. The aggregate rating reviews the ETF's overall performance and is categorized as strong sell, sell, reduce, hold, moderate buy, buy, or strong buy. The aggegreate price target represents the average potential upside for the consensus price target of individual holdings in the ETF.FTXH Aggregate RatingModerate Buy 2.65Holdings in FTXH have an aggregate rating of Moderate Buy based on 524 analyst ratings issued in the past year covering 25 companies (84.5% of the portfolio).FTXH Aggregate Price Target$36.02High Prediction$36.02Average Prediction$36.02Low Prediction$36.02Holdings in FTXH have an aggregate price target of $36.02 and a range of $36.02 to $36.02 covering 25 companies (84.5% of the portfolio).FTXH Consensus Ratings of HoldingsStrong Buy0 Strong Buy rating(s)Buy0 Buy rating(s)Moderate Buy16 Moderate Buy rating(s)Hold9 Hold rating(s)Reduce0 Reduce rating(s)Sell0 Sell rating(s)Strong Sell0 Strong Sell rating(s) Ratings for Stocks Held by First Trust Nasdaq Pharmaceuticals ETF Strong Sell Sell Reduce Hold Moderate Buy Buy Strong Buy Ratings for the Top 25 FTXH Holdings ExportWeight In ETFCompanyShare PriceMarketRank™Consensus Rating ScoreConsensus Price TargetPossible UpsideNumber of RatingsIndicator(s)ViewRatings7.95%LLYEli Lilly and Company$1,137.01+0.4%4.1028 of 5 stars2.87$1,227.74 8.0%30Trending NewsAnalyst RevisionGap Up7.10%ABBVAbbVie$227.54-0.1%4.4846 of 5 stars2.88$253.43 11.4%25Trending News7.06%MRKMerck & Co., Inc.$119.05+0.0%4.468 of 5 stars2.68$128.18 7.7%19Trending NewsOptions VolumeGap Up6.97%JNJJohnson & Johnson$240.57-0.1%4.417 of 5 stars2.74$253.04 5.2%27Trending NewsInsider Trade6.62%BMYBristol Myers Squibb$57.05-0.1%4.7181 of 5 stars2.37$61.31 7.5%19Trending News3.96%VTRSViatris$16.483.2458 of 5 stars2.43$17.50 6.2%7News CoveragePositive News3.79%BIIBBiogen$200.053.5817 of 5 stars2.55$217.26 8.6%293.40%PFEPfizer$26.19-0.1%3.8621 of 5 stars2.25$28.82 10.1%20Trending NewsAnalyst Downgrade3.39%CAHCardinal Health$223.760.0%4.0914 of 5 stars2.94$246.93 10.4%17Analyst Downgrade3.28%VRTXVertex Pharmaceuticals$444.920.0%4.6416 of 5 stars2.88$555.91 24.9%25Trending News3.24%AMGNAmgen$355.203.8153 of 5 stars2.48$354.12 -0.3%31Trending NewsAnalyst Forecast3.08%GILDGilead Sciences$125.594.9212 of 5 stars2.86$156.93 25.0%29Trending NewsAnalyst Revision2.98%UTHRUnited Therapeutics$545.964.2123 of 5 stars2.85$619.42 13.5%13Insider Trade2.88%REGNRegeneron Pharmaceuticals$612.144.8595 of 5 stars2.70$792.65 29.5%27Positive News2.54%JAZZJazz Pharmaceuticals$230.563.3405 of 5 stars2.84$246.06 6.7%19Trending NewsInsider Trade2.34%INCYIncyte$108.532.8442 of 5 stars2.32$105.10 -3.2%222.29%ZTSZoetis$79.51-0.1%4.9672 of 5 stars2.33$133.92 68.4%15Trending NewsGap Up1.94%ILMNIllumina$160.972.2516 of 5 stars2.33$142.13 -11.7%18Positive NewsGap Up1.80%EXELExelixis$53.133.08 of 5 stars2.39$47.35 -10.9%23Positive News1.44%NBIXNeurocrine Biosciences$159.763.8519 of 5 stars2.87$187.52 17.4%231.34%MEDPMedpace$467.342.1477 of 5 stars2.20$467.08 -0.1%15Gap Up1.34%CRLCharles River Laboratories International$187.39-0.1%2.5916 of 5 stars2.63$208.50 11.3%161.33%PTCTPTC Therapeutics$75.143.3304 of 5 stars2.71$91.36 21.6%14Positive NewsInsider Trade1.23%ALKSAlkermes$44.282.3272 of 5 stars2.76$46.13 4.2%171.21%BMRNBioMarin Pharmaceutical$55.954.5188 of 5 stars2.75$88.67 58.5%24 This page (NASDAQ:FTXH) was last updated on 6/15/2026 by MarketBeat.com Staff. From Our PartnersTrump Takes Emergency Action - Plus Elon Musk's New VentureElon Musk has quietly launched a new venture - one that has nothing to do with rockets, EVs, or Neuralink. Tru...Altimetry | SponsoredIs SpaceX really worth 1.78 Trillion?With SpaceX approaching a near-$2 trillion valuation, most investors are focused on the IPO itself - but analy...InvestPub | SponsoredHey, it's Jon Najarian. The SpaceX IPO is right around the corner. But I discovered Elon may have something BIGGER planned. Check this out before June 9th...After being invited to the SpaceX launch headquarters in Cape Canaveral from one of Elon's top lobbyists… Hall...Banyan Hill Publishing | SponsoredSpaceX is chump change compared to Elon’s $20T ‘iPhone’Early Apple investors saw peak gains as high as 7,537% after the iPhone launched. Now, multiple insider source...StocksToTrade | SponsoredThe roadshow starts Monday. This stock isn't ready.The SpaceX roadshow kicks off June 8. Goldman Sachs, the lead underwriter, will present the full S-1 to the wo...Behind the Markets | SponsoredStranded On The Flood Plains of HistoryThe petrodollar arrangement that Kissinger brokered in 1974 officially expired in June 2024. China has slashed...Porter & Company | SponsoredThis is the worst news for stocks in 50 yearsGoldman Sachs and Morgan Stanley are issuing a rare warning: what's ahead for U.S. stocks could be the worst e...TradeSmith | SponsoredElon’s new "tollbooth"The upcoming SpaceX IPO - reported for June 12 - is valued at $1.75 trillion. But one analyst says fighting ov...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding First Trust Nasdaq Pharmaceuticals ETF Please log in to your account or sign up in order to add this asset to your watchlist. Share First Trust Nasdaq Pharmaceuticals ETF With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
